Re: Alzheimer’s drugs take a new tack
Addressing chronic diseases of the CNS such as Alzheimer’s is clearly a challenging and risky proposition. It is important to ask whether current R & D strategies are the best way...
View ArticleRe: Alzheimer’s drugs take a new tack
Very interesting and balanced article. Many of us who have been involved in AD reserach and drug discovery understand the challenges. The positive outcome from Lilly trial (regardless of statistical...
View ArticleRe: Alzheimer’s drugs take a new tack
Part of the failure to find treatments for Alzheimer’s disease may, paradoxically, be the amount of money involved. The only intervention known to make a difference...
View ArticleRe: Alzheimer’s drugs take a new tack
The amyloid prevention trial of antibodies has not proven successful at least in the patients studied so far. Perhaps with new imaging techiques for amyloid, milder forms of cognitive impairment in the...
View ArticleRe: Alzheimer’s drugs take a new tack
Amyloid hypothesis' new dressIn 1906, Alois Alzheymer described the tangles and plaques, which define the neuropathology of Alzheymer's disease (AD). The question was whether the tangles and plaques...
View Article